STA9090 as a Potential Therapeutic Agent for Liver Fibrosis by Modulating the HSP90/TβRII/Proteasome Interplay: Novel Insights from In Vitro and In Vivo Investigations

STA9090 as a Potential Therapeutic Agent for Liver Fibrosis by Modulating the HSP90/TβRII/Proteasome Interplay: Novel Insights from In Vitro and In Vivo Investigations

Liver fibrosis is a progressive condition characterized by the build-up of fibrous tissue resulting from long-term liver injury. Although there have been advancements in research and treatment, there is still a need for effective antifibrotic medication. HSP90 plays a crucial role in the development...

Full description

Bibliographic Details
Main Authors: Osama A. Mohammed, Mustafa Ahmed Abdel-Reheim, Mohannad Mohammad S. Alamri, Jaber Alfaifi, Masoud I. E. Adam, Lobna A. Saleh, Alshaimaa A. Farrag, Amar Ibrahim Omer Yahia, Sameh Abdel-Ghany, AbdulElah Al Jarallah AlQahtani, Emad Bahashwan, Hanan B. Eltahir, Nahid A. Mohammed, Hend S. El-wakeel, Sara H. Hazem, Sameh Saber
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Pharmaceuticals
Subjects:
liver fibrosis
STA9090
HSP90
TGF-β
TβRII
proteasome
Online Access:https://www.mdpi.com/1424-8247/16/8/1080

Internet

https://www.mdpi.com/1424-8247/16/8/1080

Similar Items